Phase 2 trial in 354 participants with moderate-to-severe SLE: enpatoran did not meet its primary objective of a significant dose-response in week-24 BICLA response (p=0.14); response was 49-58% across doses vs 39% with placebo.
RCTn = 354
Morand et al. Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial